ClinicalTrials.Veeva

Menu

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 1

Conditions

Obesity

Treatments

Drug: AZD4017
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01096004
D2060M00001

Details and patient eligibility

About

The primary purpose of this study is to investigate different methods to evaluate the effect of AZD4017 in adipose tissue after single and multiple doses of AZD4017 in abdominally obese but otherwise healthy subjects.

Enrollment

15 patients

Sex

Male

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Provision of signed written and dated informed consent
  • Have a body mass index (BMI) between 27 and 35 kg/m2
  • Waist circumference of >102 cm

Exclusion criteria

  • History of any clinical significant disease
  • Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product
  • Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator

Trial design

15 participants in 2 patient groups, including a placebo group

1
Experimental group
Treatment:
Drug: AZD4017
2
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems